Table 4 Performance of HIV/HBV/HCV multiplex POC tests [38]
From: The future of viral hepatitis testing: innovations in testing technologies and approaches
Company | Specimen | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|
OraSure | HCV Antibody Test | 92.7% (88.8%–96.5%) | 99.8% (99.4%–100%) |
Chembio | HCV Screen | 92.1% (87.7%–96.4%) | 99.2% (98.6%–99.9%) |
HIV-HCV Assay | 91.5% (87.2%–95.7%) | 99.4% (98.8%–99.9%) | |
HIV-HCV-Syphilis | 92.3% (88.4%–96.2%) | 99.3% (98.8%–99.9%) | |
MedMira | HIV/HCV | 79.1% (72.6%–85.5%) | 100% |
HIV/HCV/HBV | 81.5% (75.2%–87.8%) | 100% |